Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662861 | 0.93 | NPC1 (0.58) | NPC1MAPTMEN1HSP90AA1PKM | |
| SCHEMBL2309322 | 0.86 | KMT2A (0.73) | NPC1MAPTMEN1HSP90AA1PKM | |
| SCHEMBL6708262 | 0.82 | POLB (0.58) | SMN1; SMN2NPC1MAPTMEN1KMT2A | |
| SCHEMBL3595597 | 0.82 | HTT (0.70) | SMN1; SMN2NPC1MAPTMEN1HSP90AA1 | |
| SCHEMBL10246421 | 0.81 | MEN1 (0.59) | SMN1; SMN2MAPTMEN1HSP90AA1KMT2A | |
| SCHEMBL11120915 | 0.81 | KCNH2 (0.76) | NPC1MAPTMEN1KMT2APOLB | |
| SCHEMBL6591899 | 0.81 | LMNA (0.74) | SMN1; SMN2NPC1MAPTMEN1PKM | |
| SCHEMBL9423772 | 0.80 | MAPT (0.75) | SMN1; SMN2NPC1MAPTMEN1HSP90AA1 | |
| SCHEMBL2153018 | 0.80 | MAPT (0.59) | SMN1; SMN2NPC1MAPTMEN1HSP90AA1 | |
| SCHEMBL1663714 | 0.80 | MEN1 (0.54) | SMN1; SMN2NPC1MAPTMEN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963276-B9 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-09-26 | — | — | EP | disclosed |
| EP-1963276-B1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-06-20 | — | — | EP | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | SMN1; SMN2 4852/4885NPC1 611/4885MAPT 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.